The plan to file Lentiglobin for sickle cell disease next year gets the green light, as a patient death is deemed unrelated to treatment.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.
A week after one Bristol-Myers Squibb approval decision was delayed a second suffers a similar fate, and the group’s CVR slowly unravels.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Belantamab’s registrational Dreamm-2 study comes up short of an earlier trial and, more importantly, now seriously lags competitors’ data.